$CABR (Caring Brands) filed to list on Nasdaq — a wellness consumer products co led by Photocil, a narrow-band UV filter for vitiligo and psoriasis. It's being separated from Safety Shot. The headline

Financials are nominal: roughly $4,215 in revenue in 2025 vs $465 the prior year, with losses widening to about $6.28 million. Photocil launched in India in Q3 2022, was pulled from the U.S. after a brief 2022-23 run on weak sales, and a U.S. relaunch is targeted for 2026. Risks stack up: limited operating history as a public company, historical financials that may not reflect future results, uncertainty around realizing Separation benefits from Safety Shot, and a concurrent registered offering that could pressure price, demand, and liquidity. Use of proceeds wasn't detailed in the filing data provided — worth watching for in the full prospectus. Bottom line: near-zero revenue, going-concern-style losses, heavy dilution risk, four employees, no analyst coverage. This is a speculative, thinly traded microcap — size positions accordingly and don't confuse the Nasdaq ticker with substance.

Financials are nominal: roughly $4,215 in revenue in 2025 vs $465 the prior year, with losses widening to about $6.28 million. Photocil launched in India in Q3 2022, was pulled from the U.S. after a b